PROSPECTUS SUPPLEMENT
(To Prospectus Dated November 16, 2016)
$200,000,000
![LOGO](https://capedge.com/proxy/424B5/0001193125-19-162820/g721713g12p15.jpg)
6.25% Convertible Senior Notes due 2024
We are offering $200,000,000 aggregate principal amount of our 6.25% Convertible Senior Notes due 2024 (or the notes) under this prospectus supplement. The notes will bear interest at a rate equal to 6.25% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on December 15, 2019. The notes will mature on June 15, 2024, unless earlier converted, redeemed or repurchased.
Holders may convert their notes into shares of our common stock, $0.01 par value per share, at any time prior to the close of business on the business day immediately preceding the maturity date. The conversion rate will initially equal 125.7387 shares of common stock per $1,000 principal amount of notes (equivalent to a conversion price of $7.95 per share of common stock). The conversion rate will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following the occurrence of a make-whole fundamental change, we will, in certain circumstances, increase the conversion rate for a holder that converts its notes in connection with such make-whole fundamental change.
We may not redeem the notes prior to maturity, except to the extent necessary to preserve our status as a real estate investment trust, or REIT, for U.S. federal income tax purposes, as further described in this prospectus supplement. No sinking fund will be provided for the notes.
Upon the occurrence of a fundamental change, holders may require us to purchase the notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date.
The notes will be our senior unsecured obligations and will rank senior in right of payment to any future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to our existing and future unsecured indebtedness that is not so subordinated, including our 8.00% Senior Notes due 2042, effectively junior to any future secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior to all existing and future indebtedness and any preferred equity of our subsidiaries as well as to any of our existing or future indebtedness that may be guaranteed by any of our subsidiaries (to the extent of any such guarantee).
We do not intend to apply for listing of the notes on any securities exchange. Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “MFA”. The closing price of our common stock on the NYSE on May 29, 2019 was $7.23 per share.
We have elected to be treated as a real estate investment trust, or REIT, for U.S. federal income tax purposes. In order to maintain our qualification as a REIT, we must comply with a number of requirements under U.S. federal income tax law that are discussed under the heading “Material U.S. Federal Income Tax Considerations” in the accompanying prospectus. Our charter contains restrictions on the ownership and transfer of our capital stock that are intended to assist us in complying with the requirements for qualification as a REIT. Among other things, our charter provides that, subject to certain exceptions, no person or entity may actually or beneficially own, or be deemed to own by virtue of the applicable constructive ownership provisions of the Internal Revenue Code of 1986, as amended, more than 9.8% (in value or in number of shares, whichever is more restrictive) of the outstanding shares of our capital stock. See “Description of Common Stock and Preferred Stock—Restrictions on Ownership and Transfer” in the accompanying prospectus. In addition, we intend to conduct our business at all times so as to maintain our exempt status under, and not to become regulated as an investment company for purposes of, the Investment Company Act.
Investing in the notes involves risks that are described under the caption “Risk Factors” beginning onpage S-7 of this prospectus supplement and in our Annual Report on Form10-K for the fiscal year ended December 31, 2018 and as updated by our subsequent Quarterly Reports on Form10-Q and Current Reports on Form8-K, which are incorporated by reference in this prospectus supplement.
| | | | | | | | |
| | Per Note | | | Total(1) | |
Public offering price(2) | | | 99.0 | % | | $ | 198,000,000 | |
Underwriting discounts and commissions(3) | | | 1.75 | % | | $ | 3,500,000 | |
Proceeds to us (before expenses) | | | 97.25 | % | | $ | 194,500,000 | |
(1) | Assumes no exercise of the underwriters’ over-allotment option. |
(2) | Plus accrued interest, if any, from June 3, 2019. |
(3) | See “Underwriting” for a description of compensation payable to the underwriters. |
Neither the Securities and Exchange Commission, or SEC, nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
We have also granted the underwriters an option to purchase within 30 days from the date of this prospectus supplement up to an additional $30,000,000 principal amount of notes from us at the initial public offering price less the underwriting discounts and commissions solely to cover over-allotments, if any.
The underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository Trust Company on or about June 3, 2019.
Joint Book-Running Managers
| | | | | | |
Morgan Stanley | | Goldman Sachs & Co. LLC | | Barclays | | Wells Fargo Securities |
The date of this prospectus supplement is May 29, 2019